Meridian Health Systems: Working Capital, Capitalized Software, and the Adjusted EBITDA Story
Meridian Health Systems (MRDN) reports FY revenue of $840 million, up 14%, and net income of $95 million. Days sales outstanding rose from 62 to 81, deferred revenue fell $22 million, and operating cash flow was $71 million. Capitalized software development jumped from $8 million to $31 million; previously these costs were expensed. Management reports adjusted EBITDA of $162 million, adding back $18 million of stock compensation, $12 million of restructuring, $9 million of ERP implementation costs, and $6 million of acquisition integration costs - the last of which has appeared in each of the past three years. Total debt is $620 million and the company reports net leverage of 3.8x. Management tells investors the story is 'growth plus margin expansion.'
1. Quantify what the working capital and capitalization trends imply about the quality and repeatability of the 14% growth.
Read the worked answer
The growth is substantially funded by the balance sheet.
- Receivables: 19 extra DSO on $840 million is roughly $44 million of receivables that growth pulled forward ($840 × 19/365). Revenue recognized ahead of cash collection.
- Deferred revenue: a $22 million decline means billings collected in advance of recognition fell - a tailwind to reported revenue that reverses when the pipeline refills or, worse, signals softening bookings.
- Together those two items are about $66 million, roughly two-thirds of the $103 million revenue increase ($840 − $840/1.14 ≈ $103 million). Two-thirds of the growth is matched by a working capital build rather than by cash.
- Cash conversion: OCF/net income is 0.75x, already weak. But OCF is flattered by the capitalization shift: if the $31 million now capitalized had been expensed, OCF would be roughly $40 million, about 0.4x net income.
- The capitalization flip is the tell. Moving from expensing to capitalizing $31 million does three things at once: it raises EBITDA, it raises operating cash flow (the spend moves to investing), and the incremental $23 million versus last year is almost exactly the kind of number that turns a flat year into a 'margin expansion' year.
Conclusion: the reported 14% is a billed number, not a collected number, and the margin story is partly an accounting classification decision.
2. Normalize EBITDA and recompute leverage. Which add-backs survive scrutiny, and what does the debt load look like on a defensible basis?
Read the worked answer
Start from $162 million and test each add-back on recurrence, not on the label management gave it.
- Stock compensation, $18 million: a real economic cost and a real dilution cost, but it is not cash out the door. Common practice is to leave it added back while flagging that it is ~11% of revenue and rising. Disclose both figures.
- Restructuring, $12 million: ask for the history. If it has appeared in three of the last five years, it is a recurring cost of running the business and should come out. Assume it goes.
- ERP implementation, $9 million: genuinely non-recurring if the project has a defined completion date and the spend steps down. Keep the add-back, but verify against the project timeline; implementation costs that persist as maintenance become operating expense.
- Acquisition integration, $6 million: in each of the last three years. That is an operating cost. Remove it.
Normalized EBITDA on that basis is about $156 million. Then normalize the capitalization policy: the $23 million incremental shift is an expense that was reclassified, so deduct it, giving about $133 million. If all $31 million is really maintenance development, the figure falls to about $125 million.
Leverage: $620 million / $162 million = 3.8x as reported; / $156 million = 4.0x; / $133 million = 4.7x; / $125 million = 5.0x. The gap between 3.8x and 5.0x decides whether this credit is comfortably inside or pressing against a covenant, so the covenant definitions - which usually lock in management's add-backs - must be read before drawing a conclusion.
3. Which specific disclosures would you pull to confirm or refute your read, and what would change your mind?
Read the worked answer
Work from the notes and the contract balances, not from the press release.
- Revenue recognition policy and the contract asset/liability roll-forward. Did the mix shift toward distributor or government customers with longer payment terms? Were there contract modifications or extended payment terms granted late in the year? A modification that spreads revenue over a longer period can flatter this quarter and hurt the next.
- Receivables aging and the allowance for credit losses. Rising DSO with a flat or falling allowance is a red flag; check customer concentration and whether any large account is past due.
- Capitalized software note. What costs qualify, what is the amortization period, how much was amortized this year, and is there any impairment testing discussion? A lengthening amortization period is a second, quieter earnings lever.
- Segment and geographic detail. Where is the growth actually coming from - recurring or one-time, new logos or price?
- Critical accounting estimates and subsequent events. Any change in estimate is a change in earnings quality.
What would change my mind: evidence the DSO increase is a planned mix shift into a channel that reliably pays at 80 days, plus a bookings metric that shows deferred revenue rebuilding in the first quarter. Absent that, the burden is on management to show cash collection, not on the analyst to prove deterioration.